Friday, October 23, 2026

2:55 PM - 3:40 PM

Industry & Ecosystems Breakout Room

---

Details

As the United States intensifies its pursuit of Most-Favored-Nation drug pricing, the implications are reverberating across global pharmaceutical markets. This session examines how linking U.S. prices to those in other countries could reshape launch sequencing, international reference pricing, licensing negotiations, market access and investment decisions. Industry leaders will explore how pharmaceutical and biotechnology companies are adapting their commercialisation and partnership strategies amid pressure on pricing and healthcare budgets. The discussion will consider what these shifts mean for Europe and Asia-Pacific, with a particular focus on Australia’s pricing sustainability, reimbursement environment, patient access, and position within global launch and innovation strategies.

---

Speaker